logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Receptos, Inc.


USPTO Granted Patents = 25



Trademarks = 2

Forward Citations = 72

Loading Chart...
Loading Chart...

49 inventors (with patents filed for the assignee):

goldMedal Junko Tamiya (12 out of 25 patents)

silverMedal Liming Huang (11 out of 39 patents)

bronzeMedal Manisha Moorjani (10 out of 25 patents)

4.  Marcus F Boehm (10 out of 64 patents)

5.  Esther Martinborough (10 out of 77 patents)

6.  Adam Richard Yeager (10 out of 32 patents)

7.  Enugurthi Brahmachary (8 out of 18 patents)

8.  Thomas Fowler (7 out of 14 patents)

9.  Yanfeng Zhang (6 out of 59 patents)

10.  Minhua Chen (6 out of 55 patents)

11.  Chaohui Yang (6 out of 16 patents)

12.  Andrew Richard Novak (6 out of 19 patents)

13.  Xiaoting Zhai (6 out of 9 patents)

14.  Kaiqiang Yan (6 out of 8 patents)

15.  Premji Meghani (6 out of 40 patents)


25 patents:

1. 12428386 - Sphingosine 1 phosphate receptor modulators (2025-09-30),
2. 12421199 - Sphingosine 1 phosphate receptor modulators (2025-09-23),
3. 12364686 - Sphingosine 1 phosphate receptor modulators (2025-07-22),
4. 11964005 - Methods of treating atopic dermatitis (2024-04-23),
5. 11897848 - Crystalline forms of ozanimod and processes for preparation thereof (2024-02-13),
6. 11680050 - Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof (2023-06-20),
7. 11530205 - GLP-1 receptor modulators (2022-12-20),
8. 11278526 - Compounds and methods for treating lupus (2022-03-22),
9. 11207301 - Sphingosine 1 phosphate receptor agonists for neuroprotection (2021-12-28),
10. 11117876 - Crystalline form of ozanimod hydrochloride, and processes for preparation thereof (2021-09-14),
11. 11111223 - Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof (2021-09-07),
12. 11066395 - Dimethylaminoethanol salt of a GLP-1 receptor modulator (2021-07-20),
13. 11040954 - CXCR3 receptor agonists (2021-06-22),
14. 11028060 - Crystalline forms of ozanimod and processes for preparation thereof (2021-06-08),
15. 10882830 - Crystal form of ozanimod hydrochloride and processes for preparation therefor (2021-01-05),
Receptos, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative therapeutics for immune and metabolic diseases. With a focus on small molecule drugs, Receptos is committed to advancing the treatment options available to patients with serious medical conditions. Visit their website to learn more about their research, pipeline, and latest developments.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

25 Patents

#230 in San Diego, CA

#3,059 in California

#12,921 in US

#24,952 in the World

...
San Diego, CA, United States of America

Receptos, Inc.

Forward Citations = 72

49 inventors:

goldMedal Junko Tamiya (12 out of 25 patents)

silverMedal Liming Huang (11 out of 39 patents)

bronzeMedal Manisha Moorjani (10 out of 25 patents)

4.  Marcus F Boehm (10 out of 64 patents)

5.  Esther Martinborough (10 out of 77 patents)

Please report any incorrect information to support@idiyas.com
Loading…